Ibuprofen Could be the Key to Colorectal Cancer Prevention

Lauren Santye, Assistant Editor

Publish Date: Friday, January 06, 2017

Nonsteroidal anti-inflammatory drugs (NSAIDs) have been proven to be beneficial in the

prevention of advanced neoplasia recurrence after polyp removal.

Advanced neoplasia are polyps that are the precursor of colorectal cancer. In fact, more than one-
third of individuals with colorectal cancer will die of the disease, with most of those cancers
arising from advanced neoplasia, accord to the World Cancer Research Fund.

In a study published in The BMJ, investigators sought to demonstrate the superiority of nonaspirin
NSAIDs compared with aspirin or nutritional supplements to prevent the growth of advanced
adenomas.

“Approximately 85% of all colorectal cancers are thought to result from untreated adenomatous
polyps,” said senior author Hassan M. Murad, MD. “If we can find a way to stop their growth, we
could prevent a majority of these cases.”

Preventing polyp growth is a good proxy for colorectal cancer prevention, according to the
authors. This is because most colorectal cancers develop from this type of polyp.

“We knew that aspirin and other NSAIDs have a protective effect, and that a number of other
nutritional supplements have also been studied for their effectiveness in preventing cancer,” Dr
Murad said. “What we didn’t know is how they compared to each other.”

The investigators conducted a meta-analysis of data from 15 randomized, controlled clinical trials
that included 12,234 patients. The studies included low- and high-dose aspirin therapy, folic acid,
vitamin D, and calcium. Each were compared alone or in various combinations, according to the
study.

The results showed that within 3 to 5 years following the initial polyp removal, the nonaspirin
NSAIDs were more effective in preventing recurrence of adenomatous polyps than all the other
compared therapies.

The study authors noted that since nonaspirin NSAIDs do have some adverse effects, it might not
be a suitable option for everyone. Aspirin had nearly similar results, with much less added risk,
according to the authors. However, Dr Murad cautions that although low-dose aspirin was ranked
second in preventive capabilities, “the excess benefit over risk might therefore be favorable for
many patients.”
“It is important that patients and doctors have a discussion on the various risks and benefits of
any medication or other therapy,” Dr Murad added. “While a research publication may contain
promising findings, it is generalized information, and each individual is different. So their care will
be individualized, as well.”
 

Stay up to date on the latest news in specialty pharmacy by getting Specialty Pharmacy Times in your mailbox or inbox for free!

Click here to sign up for free for the bi-monthly Specialty Pharmacy Times print journal delivered to your address.

Click here to sign up for our email newsletters delivered every Monday, Wednesday, and Friday, in addition to breaking news
alerts.

Click here to follow us on Facebook. 

Click here to follow us on Twitter. 

Click here to join our LinkedIn group. 

Most Popular

FDA Issues Warning Over Unapproved 'Cancer Cure'

Ibuprofen Could be the Key to Colorectal Cancer Prevention

Explore the Impact of Direct and Indirect Remuneration Fees on Specialty Pharmacy

Related Articles
Grilled Meat Consumption Increases Mortality Risk Among Breast Cancer Survivors
Higher intake of grilled, barbecued, and smoked meats increases mortality risk among cancer survivors.

Cancer Cells Respond to Diabetes, Hypertension Drug Combination

Drug combination more effective on cancer cell proliferation.

FDA Issues Warning Over Unapproved 'Cancer Cure'

A drug marketed as a potential cure for cancer has not been approved for any indications and may contain harmful
bacteria.

Company Profile >

Contributor >
Industry Guide >
Market News >
Peer Exchange >
Subscribe >
Specialty Times Resources
About Us
Advertise
Careers
Contact Us
Tech-Specs
Terms & Conditions
Privacy
MJH Associates >
Pharmacy Times
OTCGuide
American Journal of Managed Care
Cure
HCPLive
ONCLive
Targeted Oncology
Physicians' Education Resource
Intellisphere, LLC
2 Clarke Drive
Suite 100
Cranbury, NJ 08512
P: 609-716-7777
F: 609-716-4747

Copyright Specialty Pharmacy Times 2006-2017

Intellisphere, LLC. All Rights Reserved.